Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.585 USD | +4.78% | +1.82% | -0.88% |
04:37pm | UBS Adjusts Monte Rosa Therapeutics Price Target to $20 From $22, Maintains Buy Rating | MT |
Mar. 14 | Monte Rosa Therapeutics Q4 Net Loss Narrows; Shares Decline | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.88% | 268M | |
+2.09% | 42.75B | |
+47.58% | 41.61B | |
+12.37% | 41.34B | |
-12.36% | 26.59B | |
+8.74% | 25.49B | |
-23.20% | 18.12B | |
+30.25% | 12.24B | |
-1.57% | 11.76B | |
+8.95% | 11B |
- Stock Market
- Equities
- GLUE Stock
- News Monte Rosa Therapeutics, Inc.
- Wedbush Starts Monte Rosa Therapeutics With Outperform Rating, $11 Price Target